Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9321356 | 0.98 | TDP1 (0.58) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL8631405 | 0.98 | TDP1 (0.58) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL4474428 | 0.95 | MEN1 (0.62) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL27184888 | 0.93 | MEN1 (0.52) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL6534839 | 0.93 | MEN1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL4478961 | 0.90 | MEN1 (0.68) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL18760388 | 0.89 | MEN1 (0.53) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL24533591 | 0.88 | MEN1 (0.59) | MEN1KMT2AGAATDP1CA1 | |
| SCHEMBL22961926 | 0.85 | MEN1 (0.54) | MEN1KMT2AGAATDP1CA1 | |
| Hydrochloric Acid SCHEMBL9416400 | 0.84 | MEN1 (0.52) | MEN1KMT2AGAATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4914226-A | Malonic acid derivatives and methods for their synthesis | ENIRICERCHE S.P.A. (IT) | 1990-04-03 | — | — | US | claimed |
| EP-0254080-A2 | Malonic acid derivatives and methods for their synthesis | ENIRICERCHE S.p.A. (IT) | 1988-01-27 | — | — | EP | claimed |
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | disclosed |
| US-20250027130-A1 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023164676-A1 | METHODS TO GENERATE NOVEL ACYL-TRNA SPECIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | disclosed |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | disclosed |
| EP-3735276-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-0254080-B1 | MALONIC ACID DERIVATIVES AND METHODS FOR THEIR SYNTHESIS | ENIRICERCHE S.p.A. (IT) | 1993-03-17 | — | — | EP | disclosed |
| EP-0253190-B1 | PARTIALLY RETRO-INVERTED TUFTSIN ANALOGUES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ENIRICERCHE S.p.A. (IT) | 1992-12-30 | — | — | EP | disclosed |
| US-4914226-A | Malonic acid derivatives and methods for their synthesis | ENIRICERCHE S.P.A. (IT) | 1990-04-03 | — | — | US | disclosed |
| US-4816560-A | STORAGE STABILITY | ENIRICERCHE S.P.A. (IT) | 1989-03-28 | — | — | US | disclosed |
| EP-0254080-A2 | Malonic acid derivatives and methods for their synthesis | ENIRICERCHE S.p.A. (IT) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | LDLR, NPC1L1, ABCB4 | MEN1 1858/4885KMT2A 2787/4885GAA 359/4885 |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | LDLR, NPC1L1, ABCB4 | MEN1 1858/4885KMT2A 2787/4885GAA 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.